James Brumley

James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

3 Stocks That Should Amp Up Their Dividends — And Soon!

By James Brumley, InvestorPlace Feature Writer

These three companies do dole out some of their money to investors ... but still have left way too much cash sitting on the sidelines.

Online Gambling Is Set to Explode; Who’s Holding a Hot Hand?

By James Brumley, InvestorPlace Feature Writer

The potential for expanded online real-money gaming in the U.S. has had investors aflutter over several stocks -- but which could really make a dent?

If Not Amgen, Who’s Next in Line to Buy Onyx?

By James Brumley, InvestorPlace Feature Writer

A few larger players could make attractive suitors for Onyx Pharmaceuticals and its cancer drugs, but the key is whether they'll trump an already frothy bid

Will Gold’s Miserable First Half of 2013 Linger Into the Second Half?

By James Brumley, InvestorPlace Feature Writer

Gold spent the first half of 2013 diving from the $1,700 level to around $1,200. But will the yellow metal continue its a downward spiral for the next six months?

5 Dividend Stocks That Just Got Trumped by Treasuries

By James Brumley, InvestorPlace Feature Writer

When treasury bonds were below 2%, low-yield stocks were pretty safe. But now that rates are back on the rise, these five companies are in trouble.

3 ETFs to Play Rising Bond Yields

By James Brumley, InvestorPlace Feature Writer

Rising bond yields got you down? Try one of these exchange-traded funds that will survive, if not thrive, in a rising-rate environment.

Gold’s Collapse Is Not Done

By James Brumley, InvestorPlace Feature Writer

The yellow metal's been eviscerated lately, but the charts suggest the pain isn't over for gold fans. Look for a continued plunge toward $1,200.

Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)

By James Brumley, InvestorPlace Feature Writer

The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited?

Brokerage Firm Stocks: Just Getting Started

By James Brumley, InvestorPlace Feature Writer

Brokerage firms have been demolishing market returns this year, and if investors stay bullish about the economy, there's still plenty more money to be made.

So Your DNA Can’t Be Patented … Now What?

By James Brumley, InvestorPlace Feature Writer

The Supreme Court recently ruled that identifying genes is not patentable ... which is both good and bad news for DNA-mapping companies.

Load More